3 documents found, page 1 of 1
Safety, Efficacy and Pharmacokinetics of daily optimised doses of Rifampicin fo...
Espinosa-Pereiro, J; Aguiar, A; Nara, E; Medina, A; Molinas, G; Tavares, M; Tortola, T; Ghimire, S; Alfenaar, JC; Sturkenboom, MGG; Magis-Escurra, C"Background: Higher than standard doses of rifampicin could improve the treatment outcome of drug-susceptible tuberculosis without compromising the safety of patients. Methods: We performed a systematic review of prospective clinical studies including adults with pulmonary and extrapulmonary TB receiving rifampicin doses above 10mg/kg/day. We extracted the data on overall adverse events (AE), hepatic AE, sputum...
Management of patients with multidrug-resistant tuberculosis
Lange, C; Aarnoutse, RE; Alffenaar, JWC; Bothamley, G; Brinkmann, F; Costa, J; Chesov, D; van Crevel, R; Dedicoat, M; Dominguez, J; Duarte, RThe emergence of multidrug-resistant tuberculosis (MDR-TB; defined as resistance to at least rifampicin and isoniazid) represents a growing threat to public health and economic growth. Never before in the history of mankind have more patients been affected by MDR-TB than is the case today. The World Health Organization reports that MDR-TB outcomes are poor despite staggeringly high management costs. Moreover, t...
Clinical Management of Multidrug-Resistant Tuberculosis in 16 European Countries
Guenther, G; Leth, F; Alexandru, S; Altet, N; Avsar, K; Bang, D; Barbuta, R; Bothamley, G; Ciobanu, A; Crudu, V; Danilovits, M; Dedicoat, M; Duarte, RRationale: Multidrug-resistant tuberculosis (MDR-TB) is a major burden to public health in Europe. Reported treatment success rates are around 50% or less, and cure rates are even lower. Objectives: To document the management and treatment outcome in patients with MDR-TB in Europe. Methods: We performed a prospective cohort study, analyzing management and treatment outcomes stratified by incidence of patients w...